Gao, Song
Wang, Shuaibin
Zhao, Zhiying
Zhang, Chao
Liu, Zhicao
Ye, Ping
Xu, Zhifang
Yi, Baozhu
Jiao, Kai
Naik, Gurudatta A.
Wei, Shi
Rais-Bahrami, Soroush
Bae, Sejong
Yang, Wei-Hsiung
Sonpavde, Guru http://orcid.org/0000-0002-1010-9611
Liu, Runhua http://orcid.org/0000-0002-0892-6946
Wang, Lizhong http://orcid.org/0000-0003-1980-4730
Funding for this research was provided by:
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-20-1-0426, W81XWH-21-1-0100)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA013148, CA118948)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (S10 RR027822)
Mike Slive Foundation for Prostate Cancer Research
Article History
Received: 17 November 2020
Accepted: 28 April 2022
First Online: 19 May 2022
Competing interests
: There are disclosures by Guru Sonpavde as follows. All these disclosures are unrelated to this manuscript. Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, AstraZeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals. Research Support: Sanofi, AstraZeneca, Gilead, QED, Lucence, Predicine, BMS, EMD Serono, Lucence. Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and AstraZeneca, EMD Serono, Debiopharm (paid). Data safety monitoring committee: Mereo. Employment: Spouse employed by Myriad. Travel costs: BMS, AstraZeneca. Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence. The remaining authors declare no competing interests.